RA CAPITAL MANAGEMENT, L.P.
Q2 2021 13F-HR Holdings
Net value change ($000)
-401,367
(-6.1%)
New positions
20
Sold out positions
10
Turnover %
22.7%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q1 2021
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| JANX | 216,333 | NEW |
| JBIO | 188,667 | NEW |
| DAWN | 113,066 | NEW |
| LENZ | 82,921 | NEW |
| CNTB | 81,197 | 146.7% |
| HOWL | 74,850 | NEW |
| Cyteir Therapeutics, Inc. | 69,488 | NEW |
| ASND | 68,966 | 8.3% |
| GHRS | 64,733 | NEW |
| Verve Therapeutics, Inc. | 53,037 | NEW |
Top Reduces (Value $000, Stocks/ETFs)
| VOR | -271,908 | -56.7% |
| AVIR | -216,188 | -65.2% |
| ChemoCentryx, Inc. | -135,431 | -74.3% |
| TGTX | -93,797 | -42.0% |
| ADVM | -92,347 | -100.0% |
| IGM Biosciences, Inc. | -75,365 | -100.0% |
| MCRB | -74,163 | -97.5% |
| TVTX | -58,277 | -41.6% |
| CONSTELLATION PHARMACEUTICALS INC | -52,359 | -100.0% |
| STRO | -48,211 | -100.0% |
Instrument mix + QoQ Δ (ex-options)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|